U.S. Logistics Stock News

NasdaqCM:BULL
NasdaqCM:BULLCapital Markets

Why Webull (BULL) Is Up 9.2% After Returning To Profit And Buying Back Shares

Webull Corporation recently reported its second-quarter 2026 results, with revenue rising to US$198.83 million and net income turning positive at US$24.36 million, alongside completing a US$10.98 million share repurchase of 1,820,788 shares. This shift from a loss a year earlier to profitability, aided by increased trading activity after the SEC’s Pattern Day Trader rule removal and expansion into new international markets, signals a meaningful change in Webull’s operating profile. We’ll now...
NasdaqGS:NWL
NasdaqGS:NWLConsumer Durables

Should Newell Brands’ (NWL) Debt Refi and EXPO XL Launch Reshape Its Core Investment Narrative?

Earlier this month, Newell Brands issued US$600,000,000 of 6.250% senior unsecured notes due 2031 to redeem its 6.375% notes due 2027, cover related costs and reduce borrowings under its asset-based revolving credit facility. The company also expanded its EXPO franchise with the launch of the EXPO XL marker, targeting classroom accessibility needs and rolling out across major retailers including Staples, Walmart and Amazon. We’ll now examine how this refinancing of higher-cost 2027 notes...
NasdaqGS:LYFT
NasdaqGS:LYFTTransportation

Should Lyft’s (LYFT) California Malice Finding in Worker Case Prompt Investor Reassessment of Legal Strategy?

In July 2026, a California Workers' Compensation Appeals Board judge sanctioned Lyft, Inc. a total of US$66,735 for willfully delaying discovery and repeatedly violating court orders to produce employment records in a catastrophic-injury case involving former driver Mark Nahvi, finding the company acted with malice. The ruling puts renewed focus on Lyft’s handling of worker-classification disputes in California, a long-running legal battleground for gig-economy employment models. Next, we’ll...
NasdaqCM:IMTX
NasdaqCM:IMTXBiotechs

Why Immatics (IMTX) Is Down 5.4% After Mixed First‑Half 2026 Loss Trends And What's Next

Immatics N.V. reported past second quarter 2026 results showing a net loss of €62.49 million, narrower than the prior year, while the six‑month net loss increased to €120.31 million. The company’s quarterly loss per share improved year on year, even as the cumulative loss for the first half of 2026 edged higher. Next, we will examine how Immatics’ narrower quarterly loss per share shapes its investment narrative in light of these mixed results. Uncover the next big thing with 22 elite penny...
NYSE:USPH
NYSE:USPHHealthcare

U.S. Physical Therapy (USPH) Names A New CFO On A Valuation Gap Story

U.S. Physical Therapy (USPH) has announced that Nchacha Etta will become Chief Financial Officer and Executive Vice President on September 1, 2026, a leadership change that could influence how investors view the stock. See our latest analysis for U.S. Physical Therapy. Over the past year, U.S. Physical Therapy has seen share price momentum pick up recently, with a 26.23% 3 month share price return contrasting with a 1 year total shareholder return that declined 8.24%. If this leadership...
NasdaqGS:LI
NasdaqGS:LIAuto

Li Auto (LI) Is Up 6.4% After Upgraded Mega EV Highlights Push Into Premium Ride Comfort

Earlier this month, Li Auto unveiled an updated Mega minivan that keeps its bullet-train silhouette while adding fully active suspension, a larger 108 kWh battery, dual motors with 554 hp, and an expected 441-mile CLTC range. This upgrade underlines Li Auto’s push to differentiate through high-end ride comfort and long-range battery tech in China’s premium EV segment. We’ll now examine how the fully active suspension upgrade in the Mega could influence Li Auto’s broader investment...
NasdaqCM:IMNM
NasdaqCM:IMNMBiotechs

Should Immunome’s (IMNM) Rising Losses and ESOP Shelf Offering Require Action From Investors?

In August 2026, Immunome, Inc. reported second-quarter and six‑month results showing higher net losses and loss per share than the prior year. On the same day, the company filed a US$38.54 million shelf registration for 1,500,000 common shares tied to an employee stock ownership plan, highlighting its focus on future capital flexibility. Next, we’ll consider how the widened quarterly loss shapes Immunome’s broader investment narrative for investors assessing its long-term prospects. AI is...
NasdaqGS:CART
NasdaqGS:CARTConsumer Retailing

Is Maplebear (CART) A Bargain Following Its Academy Sports Marketplace Deal?

Maplebear (CART), which operates Instacart, is back in focus after Academy Sports + Outdoors joined its Marketplace, adding same day delivery from more than 300 sporting goods stores across 21 states. See our latest analysis for Maplebear. The Academy Sports + Outdoors partnership arrives while Maplebear’s share price has risen 18.05% over the past 30 days and 20.89% over the past 90 days, with a 1 year total shareholder return of 14.90%, suggesting momentum is building from a relatively...
NYSE:SYF
NYSE:SYFConsumer Finance

Does Synchrony’s AI Pivot and OpenAI Partnership Reframe The Bull Case For Synchrony Financial (SYF)?

In mid-August 2026, Synchrony Financial reported second-quarter results that exceeded expectations, raised its 2026 EPS outlook, appointed a Chief AI Officer, and detailed an enterprise-wide collaboration with OpenAI to embed advanced models into shopping, payments, and internal operations. Together, these moves suggest Synchrony is trying to reposition itself as an AI-forward consumer finance platform, using frontier models to rewire how it manages credit risk, develops products, and powers...
NYSE:ACM
NYSE:ACMConstruction

Is AECOM’s Construction Charge And Cut Outlook Altering The Investment Case For AECOM (ACM)?

AECOM reported past third-quarter 2026 results showing sales of US$3,586.07 million and a net loss of US$86.71 million, alongside weaker year-to-date earnings versus the prior year. On the same day, the company cut its full-year 2026 outlook to factor in a Construction Management charge, delayed project starts, and disruption from Middle East conflict, even as underlying margins excluding these items were higher than expected. Next, we’ll examine how the Construction Management charge and...
NasdaqGS:REGN
NasdaqGS:REGNBiotechs

Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?

Earlier this week, Regeneron Pharmaceuticals announced that the FDA approved Pasatru (garetosmab-grts), a monthly intravenous monoclonal antibody, to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with the ultra-rare disease fibrodysplasia ossificans progressiva. The approval is based on Phase 3 OPTIMA trial data showing Pasatru cut new abnormal bone lesions to just a few cases compared with many more on placebo, while also enabling administration...
NYSE:NUVB
NYSE:NUVBPharmaceuticals

Nuvation Bio (NUVB) Gains Fast Track Backing As Fair Value Stays In Focus

Nuvation Bio (NUVB) stock is in focus after the U.S. FDA granted Fast Track Designation to safusidenib for IDH1-mutant glioma, following clinical data showing durable responses and a favorable risk-benefit profile. See our latest analysis for Nuvation Bio. At a latest share price of US$6.93, Nuvation Bio has seen a 46.82% 90 day share price return and a very large 3 year total shareholder return, although the year to date share price return is down 19.23%, which suggests momentum has picked...
NYSE:PARR
NYSE:PARROil and Gas

Par Pacific Holdings (PARR) Shares Climbed, What Is Drawing Attention Now?

Recent commentary on Par Pacific Holdings (PARR) highlighting its Zacks Rank #1 and value grade has put the stock in focus, as investors weigh its valuation metrics, earnings outlook and recent price performance. See our latest analysis for Par Pacific Holdings. Par Pacific Holdings has seen strong share price momentum over the past year, with a 1-day share price return of 9.08% and a year to date share price return of 120.63%. The 1-year total shareholder return of 153.30% points to...
NYSE:SF
NYSE:SFCapital Markets

Is Stifel Financial (SF) Undervalued Or Is Its Rebound Already Priced In?

Stifel Financial (SF) drew investor attention after its latest market close at $80.96, with recent returns reflecting a mix of short-term weakness and longer-term gains over the past month and the past three months. See our latest analysis for Stifel Financial. Over the past year, Stifel Financial has seen its share price return soften year to date, while its 90 day share price return of 11.53% and 1 year total shareholder return of 8.07% suggest that momentum has been steadier over a longer...